Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers

Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers

Targeted radiopharmaceuticals for therapeutic use deliver radionuclides directly to tumor anywhere in the body, and therefore, have renewed interest for clinical development in women with disseminated chemorefractory ovarian cancers. About two in every five women with advanced stage ovarian cancer o...

Full description

Bibliographic Details
Main Authors: Charles A. Kunos, Jacek Capala, Shanda Finnigan, Gary L. Smith, Susan Percy Ivy
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-03-01
Series:Frontiers in Oncology
Subjects:
radiopharmaceutical
radiation
radionuclides
nuclear medicine
ovarian cancer
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00180/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00180/full

Similar Items